RxDoctor Payments Data

Bruce Altman, MD

Glaucoma Specialist · Danbury, CTNPI 1336147784

Payments from drug & device makers

$4,793in general payments, 2019–2025

Across 80 payments — averaging $59.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Alcon$762
  • Glaukos Corporation$491
  • Johnson & Johnson Surgical Vision, Inc.$309
  • Nova Eye, Inc.$273
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$268
  • plus $499 from 13 others

What the payments were for

  • Travel & lodging$120%
  • Food & beverage$4,781100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Connecticutto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$458,814
Medicare patients
892
Services billed
3,708

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost193$92,124
VyzultaLatanoprostene Bunod130$61,126
RocklatanNetarsudil Mesylat/Latanoprost99$54,625
RhopressaNetarsudil Mesylate44$23,282
CombiganBrimonidine Tartrate/Timolol55$20,565
Travoprost132$18,846
RestasisCyclosporine11$16,793
Latanoprost1,563$16,084
Prednisolone Acetate578$15,672
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol120$14,118
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat599$10,759
TafluprostTafluprost/Pf54$9,700
Alphagan PBrimonidine Tartrate30$9,252
Dorzolamide Hcl452$8,193
SimbrinzaBrinzolamide/Brimonidine Tart29$7,724

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$2,191$138,734289 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$23$77,907143 claims
Bausch & Lomb Americas Inc.Vyzulta$86$61,126130 claims
AlconSimbrinza$762$7,72429 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$268$6,60715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Connecticuton file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Danbury

Where these figures come from

Is this you, or does something look wrong? →